Q&A: Why people at increased risk of thrombosis are safe to get the AstraZeneca vaccine
Rare blood clots linked to the vaccine 'are a different entity'
Six Australians have now developed thrombosis with thrombocytopenia syndrome (TTS), the rare disorder associated with AstraZeneca’s COVID-19 vaccine.
Incorrect perceptions about risk are fuelling hesitancy among patients who have an increased risk or personal history of clots.
Antony Scholefield spoke with leading haematologist Professor Huyen Tran, co-author of the Thrombosis and Haemostasis Society of Australia and New Zealand’s advisory statement on TTS, also known as vaccine-induced prothrombotic immune thrombocytopenia, or VIPIT.
Australian Doctor: Let’s start with the basics. What’s the vaccination recommendation for people with a history of DVT or pulmonary embolism?
